AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (5.3 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Full Length Article | Open Access

Zinc-finger protein 382 antagonises CDC25A and ZEB1 signaling pathway in breast cancer

Shuman Lia,b,1, Xiaoqian Hec,1, Yan Wangc, Weihong Chenc, Ran Sunc, Shaorong Tianc, Sanxiu Hec, Chunyun Puc, Chen Lid, Dishu Zhouc, Yu Jiangc, Qian Taod, Lili Lid, Lin Yec, Yue Wuc, Weiyan Pengc, Tingxiu Xiangb,c,( )
Department of Oncology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, China
Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Center for Cancer, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong and CUHK Shenzhen Research Institute, Shenzhen, Guangdong 518172, China

1 These authors have contributed equally to this work.

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Abstract

Our previous studies found that Zinc-finger protein 382 (ZNF382) played as a tumor suppressor gene in esophageal and gastric cancers, and a positive correlation between the high expression of ZNF382 and better outcome in breast cancer patients. However, the biological roles and mechanisms of ZNF382 in breast cancer remains unclear. We detected ZNF382 expression by reverse-transcription PCR (RT-PCR) and real-time quantitative PCR (qRT-PCR) in breast cancer cells and tissues, and explored the impacts and mechanisms of ectopic ZNF382 expression in breast cancer cells in vitro and in vivo, respectively. Our results revealed that ZNF382 was significantly down-regulated in breast cancer tissues compared with adjacent non-cancer tissues. Restoration of ZNF382 expression in silenced breast cancer cells not only inhibited tumor cell colony formation, viability, migration and invasion, and epithelial-mesenchymal-transition (EMT), but also induced apoptosis and G0/G1 arrest. In conclusion, ZNF382 could induce G0/G1 cell cycle arrest through inhibiting CDC25A signaling, and, inhibit cell migration, invasion and EMT by antagonizing ZEB1 signaling in breast cancer cells.

Keywords

Breast cancerEMTCDC25AZEB1ZNF382

References

1

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2020;70(1):7-30, 2020.
Crossref Google Scholar
2

Kono M, Fujii T, Lim B, et al. Androgen receptor function and androgen receptor–targeted therapies in breast cancer: a review. JAMA Oncol. 2017;3(9):1266-1273.
Crossref Google Scholar
3

Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288-300.
Crossref Google Scholar
4

Goutsouliak K, Vidyalakshmi S, Carmine DA, et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020;17(4):233-250.
Crossref Google Scholar
5

Saranya T, Kavithaa K, Paulpandi M, et al. Enhanced apoptogenesis and oncogene regulatory mechanism of troxerutin in triple negative breast cancer cells. Toxicol Res (Camb). 2020;9(3):230-238.
Crossref Google Scholar
6

Hu X, Fan M. Emerging therapies for breast cancer. J Hematol Oncol. 2017;10(1):98.
Crossref Google Scholar
7

Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674-690.
Crossref Google Scholar
8

Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176-198.
Crossref Google Scholar
9

Penault-Llorca F, Radosevic-Robin N. Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nat Rev Clin Oncol. 2016;13(8):487-503.
Crossref Google Scholar
10

Margolin JF, Friedman JR, Meyer WK, et al. Kruppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci U S A. 1994;91(10):4509-4513.
Crossref Google Scholar
11

Huntley S, Baggott DM, Hamilton AT, et al. A comprehensive catalog of human KRAB-associated zinc finger genes: insights into the evolutionary history of a large family of transcriptional repressors. Genome Res. 2006;16(5):669-677.
Crossref Google Scholar
12

Tian C, Xing G, Xie P, et al. KRAB-type zinc-finger protein Apak specifically regulates p53-dependent apoptosis. Nat Cell Biol. 2009;11(5):580-591.
Crossref Google Scholar
13

Cheng Y, Geng H, Cheng SH, et al. KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res. 2010;70(16):6516-6526.
Crossref Google Scholar
14

Zhang C, Xiang T, Li S, et al. The novel 19q13 KRAB zinc-finger tumour suppressor ZNF382 is frequently methylated in oesophageal squamous cell carcinoma and antagonises Wnt/beta-catenin signalling. Cell Death Dis. 2018;9(5):573.
Crossref Google Scholar
15

Pei L, Li S, Sun R, et al. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer. Int J Oncol. 2018;53(3):961-972.
Crossref Google Scholar
16

Dang S, Chen Y, Chen P, et al. Dynamic expression of ZNF382 and its tumor-suppressor role in hepatitis B virus-related hepatocellular carcinogenesis. Oncogene. 2019;38(24):4804-4819.
Crossref Google Scholar
17

Tao YF, Hu SY, Lu J, et al. Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients. Int J Mol Med. 2014;34(6):1505-1515.
Crossref Google Scholar
18

Xiang T, Tang J, Li L, et al. Tumor suppressive BTB/POZ zinc-finger protein ZBTB28 inhibits oncogenic BCL6/ZBTB27 signaling to maintain p53 transcription in multiple carcinogenesis. Theranostics. 2019;9(26):8182-8195.
Crossref Google Scholar
19

Xiang T, Fan Y, Li C, et al. DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-tomesenchymal transition and cytoskeleton reorganization in breast cancer cells. Oncotarget. 2016;7(43):70924-70935.
Crossref Google Scholar
20

Lyer M, Mohana DS, Kaavya J, et al. New insight into NANOG: a novel therapeutic target for ovarian cancer (OC). Eur J Pharmacol. 2019;5(852):51-57.
Crossref Google Scholar
21

Vellingiri B, Lyer M, Mohana MD, et al. Understanding the role of the transcription factor Sp1 in ovarian cancer: from theory to practice. Int J Mol Sci. 2020;21(3):1153.
Crossref Google Scholar
22

Kaavya J, Verllingiri B, Kumaran SS. Ampullary carcinoma-A genetic perspective. Mutat Res Rev Mutat Res. 2018;77610-77622.
Google Scholar
23

Lupo A, Cesaro E, Montano G, et al. KRAB-zinc finger proteins: a repressor family displaying multiple biological functions. Curr Genom. 2013;14(4):268-278.
Crossref Google Scholar
24

Machnik M, Cylwa R, Kielczewski K, et al. The expression signature of cancer-associated KRAB-ZNF factors identified in TCGA pan-cancer transcriptomic data. Mol Oncol. 2019;13(4):701-724.
Crossref Google Scholar
25

Liu L, Tong Q, Liu S, et al. ZEB1 upregulates VEGF expression and stimulates angiogenesis in breast cancer. PLoS One. 2016;11(2):e0148774.
Crossref Google Scholar
26

Zhang P, Wei Y, Wang L, et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol. 2013;16(9):864-875.
Crossref Google Scholar
27

Wang S, Tian C, Xing G, et al. ARF-dependent regulation of ATM and p53 associated KZNF (Apak) protein activity in response to oncogenic stress. FEBS Lett. 2010;584(18):3909-3915.
Crossref Google Scholar
28

Xiang S, Xiang T, Xiao Q. Zinc-finger protein 545 is inactivated due to promoter methylation and functions as a tumor suppressor through the Wnt/beta-catenin, PI3K/AKT and MAPK/ERK signaling pathways in colorectal cancer. Int J Oncol. 2017;51(3):801-811.
Crossref Google Scholar
29

He J, Wu M, Xiong L, et al. BTB/POZ zinc finger protein ZBTB16 inhibits breast cancer proliferation and metastasis through upregulating ZBTB28 and antagonizing BCL6/ZBTB27. Clin Epigenet. 2020;12(1):82.
Crossref Google Scholar
30

Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93-115.
Crossref Google Scholar
31

Sarrió D, Rodriguez-Pinilla SM, Hardisson D, et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res. 2008;68(4):989-997.
Crossref Google Scholar
32

Ko YS, Lee WS, Panchanathan R, et al. Polyphenols from artemisia annua L inhibit adhesion and EMT of highly metastatic breast cancer cells MDA-MB-231. Phytother Res. 2016;30(7):1180-1188.
Crossref Google Scholar
33

Kong D, Li Y, Wang Z, Sarkar FH. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-Phenotypic cells: are they cousins or twins? Cancers. 2011;3(1):716-729.
Crossref Google Scholar
34

Marie-Egyptienne DT, Lohse I, Hill RP. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 2013;341(1):63-72.
Crossref Google Scholar
35

Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593-601.
Crossref Google Scholar
36

Burk U, Schubert J, Wellner U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9(6):582-589.
Crossref Google Scholar
Genes & Diseases
Volume 10 Issue 2,
March 2023
Pages 568-582
DOI: 10.1016/j.gendis.2021.12.019
Cite this article:
Li S, He X, Wang Y, et al. Zinc-finger protein 382 antagonises CDC25A and ZEB1 signaling pathway in breast cancer. Genes & Diseases, 2023, 10(2): 568-582. https://doi.org/10.1016/j.gendis.2021.12.019

225

Views

2

Downloads

0

Crossref

0

Web of Science

1

Scopus

0

CSCD

Altmetrics
Received: 24 May 2021
Revised: 13 November 2021
Accepted: 22 December 2021
Published: 09 February 2022
© 2022 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return